The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen

Transplantation Reviews

Volumn 26, Issue 3, 2012, Pages 201-211

  Suwelack, Barbara ^a   Malyar, Viola ^a   Koch, Martina ^b   Sester, Martina ^c   Sommerer, Claudia ^d  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

BK VIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EXPOSURE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY INFECTION; KIDNEY TRANSPLANTATION; POSTOPERATIVE INFECTION; REVIEW; RISK REDUCTION; SCREENING;

EID: 84863103806     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2011.05.002     Document Type: Review

References (88)

1. Gardner S.D., Field A.M., Coleman D.V., et al. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971, 1:1253-1257.
2. Hirsch H.H., Brennan D.C., Drachenberg C.B., et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005, 79:1277-1286.
3. Ramos E., Drachenberg C.B., Portocarrero M., et al. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin Transplant 2002, 143-153.
4. Binet I., Nickeleit V., Hirsch H.H., et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 1999, 67:918-922.
5. Dharnidharka V., Cherikh W., Abbott K.C. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009, 87:1019-1026.
6. Hirsch H.H., Steiger J. Polyomavirus BK. Lancet Infect Dis 2003, 3:611-623.
7. Agha I., Brennan D.C. BK virus and immunosuppressive agents. Adv Exp Med Biol 2006, 577:174-184.
8. Ramos E., Drachenberg C.B., Wali R., et al. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation 2009, 87:621-630.
9. Brennan D.C., Agha I., Bohl D.L., et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005, 5:582-594.
10. Hirsch H.H., Knowles W., Dickenmann M., et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002, 347:488-496.
11. Bressollette-Bodin C., Coste-Burel M., Hourmant M., et al. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. Am J Transplant 2005, 5:1926-1933.
12. Smith J.M., McDonald R.A., Finn L.S., et al. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant 2004, 4:2109-2117.
13. Pérez-Torres D., Bertrán-Pasarell J., Santiago-Delpin E., et al. Factors and outcome in BK virus nephropathy in a Hispanic kidney transplant population. Transpl Infect Dis 2010, 12:16-22.
14. Vasudev B., Hariharan S., Hussain S.A., et al. BK virus nephritis: risk factors, timing, and outcomes in renal transplant recipients. Kidney Int 2005, 68:1834-1839.
15. Bechert C.J., Schnadig V.J., Payne D.A., et al. Monitoring of BK viral load in renal allograft recipients by real-time PCR assays. Am J Clin Pathol 2010, 133:242-250.
16. Schold J.D., Rehman S., Kayler L.K., et al. Treatment for BK virus: incidence, risk factors, and outcomes for kidney transplant recipients in the United States. Transpl Int 2009, 22:626-634.
17. Johnston O., Jaswal D., Gill J., et al. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation 2010, 89:1057-1070.
18. Bohl D.L., Storch G.A., Ryschkewitsch C., et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant 2005, 5:2213-2221.
19. Ginevri F., De Santis R., Comoli P., et al. Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation 2003, 75:1266-1270.
20. Mengel M., Marwedel M., Radermacher J., et al. Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant 2003, 18:1190-1196.
21. Awadalla Y., Randhawa P., Ruppert K., et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant 2004, 4:1691-1696.
22. Prince O., Savic S., Dickenmann M., et al. Risk factors for polyoma virus nephropathy. Nephrol Dial Transplant 2009, 24:1024-1033.
23. Ramos E., Drachenberg C.B., Papadimitriou J.C., et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002, 13:2145-2151.
24. Trofe J., Gaber L.W., Stratta R.J., et al. Polyomavirus in kidney and kidney-pancreas transplant recipients. Transpl Infect Dis 2003, 5:21.
25. Dharnidharka V.R., Cherikh W.S., Neff R., et al. Retransplantation after BK virus nephropathy in prior kidney transplant: an OPTN database analysis. Am J Transplant 2010, 10:1312-1315.
26. Randhawa P.S., Khaleel-Ur-Rehman K., Swalsky P.A., et al. DNA sequencing of viral capsid protein VP-1 region in patients with BK virus interstitial nephritis. Transplantation 2002, 73:1090-1094.
27. Randhawa P., Zygmunt D., Shapiro R., et al. Viral regulatory region sequence variations in kidney tissue obtained from patients with BK virus nephropathy. Kidney Int 2003, 64:743-747.
28. Gosert R., Rinaldo C.H., Funk G.A., et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med 2008, 205:841-852.
29. Binggeli S., Egli A., Dickenmann M., et al. BKV replication and cellular immune responses in renal transplant recipients. Am J Transplant 2006, 6:2218-2219.
30. Hodur D.M., Mandelbrot D. Immunosuppression and BKV nephropathy. N Engl J Med 2002, 347:2079-2080.
31. Wiseman A.C. Polyomavirus nephropathy: a current perspective and clinical considerations. Am J Kidney Dis 2009, 54:131-142.
32. Burgos D., Lopez V., Cabello M., et al. Polyomavirus BK nephropathy: the effect of an early diagnosis on renal function or graft loss. Transplant Proc 2006, 38:2409-2411.
33. Dadhania D., Snopkowski C., Ding R., et al. Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication. Transplantation 2008, 86:521-528.
34. Issa N.C., Fishman J.A. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009, 48:772-786.
35. Trofe J., Roy-Chaudhury P., Gordon J., et al. Early steroid cessation/avoidance regimens are associated with a lower incidence of polyomavirus nephropathy compared to steroid based immunosuppression in kidney transplant recipients. Am J Transplant 2003, 3:371.
36. Lipshutz G.S., Flechner S.M., Govani M.V., et al. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant 2004, 4:2132-2134.
37. Drachenberg C.B., Hirsch H.H., Papadimitriou J.C., et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation 2007, 84:323-330.
38. Vincenti F., Friman S., Scheuermann E., et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007, 7:1506-1514.
39. Hirsch H.H., Friman S., Wiecek A., et al. Prospective study of polyomavirus BK viruria and viremia in de novo renal transplantation. Am J Transplant 2007, 7(Suppl 2). Abstract 14.
40. Hirsch H.H., Vincenti F., Friman S., et al. Prospective study of polyomavirus BK viruria and viremia in de novo renal transplantation comparing cyclosporine and tacrolimus: a multivariate analysis. Am J Transplant 2009, 9:337. (Abstract 505).
41. Huang G., Chen L.Z., Qiu J., et al. Prospective study of polyomavirus BK replication and nephropathy in renal transplant recipients in China: a single-center analysis of incidence, reduction in immunosuppression and clinical course. Clin Transplant 2010, 24:599-609.
42. Tedesco Silva H., Cibrik D., Johnston T., et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010, 10:1401-1413.
43. Acott P.D., O'Regan P.A., Lee S.H., et al. In vitro effect of cyclosporin A on primary and chronic BK polyoma virus infection in Vero E6 cells. Transpl Infect Dis 2008, 10:385-390.
44. Li Y.J., Weng C.H., Lai W.C., et al. A suppressive effect of cyclosporine A on replication and noncoding control region activation of polyomavirus BK virus. Transplantation 2010, 89:299-306.
45. Watashi K., Hijikata M., Hosaka M., et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003, 38:1282-1288.
46. Nakagawa M., Sakamoto N., Enomoto N., et al. Specific inhibition of hepatitis C virus replication by cyclosporine A. Biochem Biophys Res Commun 2004, 313:42-47.
47. Firpi R.J., Zhu H., Morelli G., et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006, 12:51-57.
48. Vahlne A., Larsson P.A., Horal P., et al. Inhibition of herpes simplex virus production in vitro by cyclosporine A. Arch Virol 1992, 122:61-75.
49. Damaso C.R., Keller S.J. Cyclosporin A inhibits vaccinia virus replication in vitro. Arch Virol 1994, 134:303-319.
50. Franke E.K., Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology 1996, 222:279-282.
51. Manitpisitkul W., Drachenberg C., Ramos Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. Transplantation 2009, 88:83-88.
52. Rocha P.N., Plumb T.J., Miller S.E., et al. Risk factors for BK polyomavirus nephritis in renal allograft recipients. Clin Transplant 2004, 18:456-462.
53. Cosio FG Amer H., Grande J.P., et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. Transplantation 2007, 83:411-416.
54. Egli A., Köhli S., Dickenmann M., et al. Inhibition of polyomavirus BK-specific T-cell responses by immunosuppressive drugs. Transplantation 2009, 88:1161-1168.
55. Schold J.D., Kaplan B. AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. Am J Transplant 2009, 9:2067-2074.
56. Acott P., O'Regan P.A., Crocker J.F. Suppression of early and chronic BK polyoma virus replication by mycophenolic acid in Vero cells. Transpl Int 2009, 22:225-231.
57. Ritter M.L., Pirofski L. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis 2009, 11:290-297.
58. Barri Y.M., Ahmad I., Ketel B.L., et al. Polyoma viral infection in renal transplantation: the role of immunosuppressive therapy. Clin Transplant 2001, 15:240-246.
59. Shi Y., Moriyama T., Namba Y., et al. Association of treatment with 15-deoxyspergualin and BK virus nephropathy in kidney allograft recipients. Clin Transplant 2007, 21:502-509.
60. Benavides C.A., Pollard V.B., Mauiyyadi S., et al. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 2007, 84:83-88.
61. Gralla J., Wiseman A.C. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3 year graft and patient survival in recent era. Transplantation 2009, 87:1712-1719.
62. Randhawa P., Brennan D.C. BK virus infection in transplant recipients: an overview and update. Am J Transplant 2006, 6:2000-2005.
63. Araki K., Turner A.P., Shaffer V.O., et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009, 460:108-112.
64. Turner A.P., Shaffer V.O., Araki K., et al. Sirolimus enhances the magnitude and quality of viral-specific CD8(+) T-cell responses to vaccinia virus vaccination in rhesus macaques. Am J Transplant 2011, 11:613-618.
65. Pearl J.P., Parris J., Hale D.A., et al. Immunocompetent T-cells with a memory-like phonotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005, 5:465-474.
66. Budde K., Becker T., Arns W., et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011, Epub ahead of print.
67. Mendez R., Gonwa T., Yang H.C., et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005, 80:303-309.
68. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004, 77:244-251.
69. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004, 77:252-258.
70. Hilton R., Tong C.Y. Antiviral therapy for polyomavirus-associated nephropathy after renal transplantation. J Antimicrob Chemother 2008, 62:855-859.
71. Howell D.N., Smith S.R., Butterly D.W., et al. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 1999, 68:1279-1288.
72. Trofe J., Hirsch H.H., Ramos E.E. Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients. Transpl Infect Dis 2006, 8:76-85.
73. Babel N., Fendt J., Karaivanov S., et al. Sustained BK viruria as an early marker for the development of BKV-associated nephropathy: analysis of 4128 urine and serum samples. Transplantation 2009, 88:89-95.
74. Womer K.L., Guerra G., Dibadj K., et al. Immunosuppression reduction for BK virus nephropathy: a case for caution. Transpl Infect Dis 2007, 9:244-251.
75. Egli A., Binggeli S., Bodaghi S., et al. Cytomegalovirus and polyomavirus BK posttransplant. Nephrol Dial Transplant 2007, 22(Suppl 8):viii72-viii82.
76. Dall A., Hariharan S. BK virus nephritis after renal transplantation. Clin J Am Soc Nephrol 2008, 3:S68-S75.
77. Ginevri F., Azzi A., Hirsch H.H., et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007, 7:2727-2735.
78. Arunachalan C., Saundh B., Hale A., et al. Incidence of polyoma viruria after renal transplantation in a steroid avoidance regimen. Am J Transplant 2007, 7(Suppl 2):537. [Abstract].
79. Ginevri F., Comoli P., Fontana I., et al. Prevention of polyomavirus BK-associated nephropathy in pediatric kidney transplantation by prospective monitoring and preemptive immunosuppression reduction. J Am Soc Nephrol 2005, 16:704A.
80. Schaub S., Hirsch H.H., Dickenmann M., et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant 2010, 10:2615-2623.
81. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009, 9(Suppl 3):S1-S155.
82. Hardinger K.L., Koch M.J., Bohl D.J., et al. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant 2010, 10:407-415.
83. Holdaas H., Bentdal Ø., Pfeffer P., et al. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 2008, 22:366-371.
84. Lebranchu Y., Thierry A., Toupance O., et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: CONCEPT study. Am J Transplant 2009, 9:1115-1123.
85. Schena F.P., Pascoe M.D., Alberu J., et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009, 87:233-242.
86. Weiss A.S., Gralla J., Chan L., et al. Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virus-associated nephropathy: a comparison of two reduction strategies. Clin J Am Soc Nephrol 2008, 3:1812-1819.
87. Wali R.K., Drachenberg C., Hirsch H.H., et al. BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation 2004, 78:1069-1073.
88. Koleilat I., Kushnir L., Gallichio M., et al. Initiation of a screening protocol for polyoma virus results in a decreased rate of opportunistic non-BK viral disease after renal transplantation. Transpl Infect Dis 2011, 13:1-8.